Most myeloma patients are familiar with the drug Revlimid (lenalidomide). Not only is it used in the frontline setting, but also in relapsed refractory myeloma and as single agent maintenance for many. It is very well tolerated for most patients but not everyone is able to take it.
Join the African American Myeloma Community Chapter as they welcome Dr. Craig Emmit Cole to discuss Revlimid, its mechanism of action, side effect profile, who it might not work for, possible risk of secondary cancers, and what is in the works for a transdermal version of the drug.
“I became a Myeloma Coach after meeting many patients who did not have a peer mentor to ask questions and find relevant information about myeloma.”
Craig Emmitt Cole, M.D. is a board-certified Hematologist who received his Bachelor of Science degree in physiology at Michigan State University and the College of Lyman Briggs, in East Lansing Michigan. Dr. Cole went on to receive his doctoral degree at the Ohio State University College of Medicine in Columbus, Ohio. He completed his Internal Medicine Residency and Hematology/Oncology Fellowship at the University of Michigan Health System, Ann Arbor, Michigan. Dr. Cole subsequently had a post-fellowship laboratory research position at the Jerome Lipper Multiple Myeloma Center of Medicine at Dana-Farber Cancer Institute in Boston, Massachusetts. This opportunity then led to him becoming an attending hematologist at Gundersen Health System in La Crosse, Wisconsin for 9 years. There he was an instructor for both the medical and nursing schools of the western campus of the University of Wisconsin School of Medicine and Public Health. He also served as Affiliate Faculty Member of Graduate Community Health Programs and Assistant Professor (Adjunct) at the University of Wisconsin-La Crosse, Department of Health Professions. While in Wisconsin, his clinical research interest was in multiple myeloma, malignant hematology, clinical apheresis, and patient reported outcomes in hematology. He then returned to the University of Michigan Rogel Cancer Center in Ann Arbor, Michigan as an Assistant Professor in the Division of Hematology/Oncology with his primary clinical and research interest being in multiple myeloma. In May of 2019, he returned to Michigan State University College of Human Medicine at Breslin Cancer Center as the Director of Clinical Research in Hematology/ Oncology and Multiple Myeloma. Dr. Cole has been participated in over 50 clinical trials in Multiple Myeloma and Malignant Hematology. He is a member of the International Myeloma Working Group, International Myeloma Society and the American Society of Hematology; he has published in national journals and presented at the American Society of Hematology International Myeloma Workshop, and the American Society for Apheresis meetings. He has lectured across the United States to patients, researchers and clinical providers in multiple myeloma, plasma cell dyscrasias, and disparities in cancer care. He has won awards for his work in student and resident teaching, multiple myeloma research, and patient advocacy. Dr. Cole has always had a strong commitment to equity of cancer care, patient empowerment, and community education by working with several local and national patient advocacy associations to bring the good news of myeloma research to everyone.
Thank you for your interest in the event. If you have any questions, we would love to help!
Feel free to give us a call or send us a message below.
+1 800 709 1113
Support@healthtree.org
Subscribe to the weekly "HealthTree Community for Myeloma Newsletter" for Myeloma news, life with Myeloma stories, Myeloma clinical trials, Myeloma 101 articles and events with Myeloma experts.